<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The bcl-3 gene at chromosome 19q13 encodes a member of the IkappaB family involved in regulating the NFkappaB pathway </plain></SENT>
<SENT sid="1" pm="."><plain>Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed BCL-3 expression in 353 cases of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods </plain></SENT>
<SENT sid="3" pm="."><plain>Of 172 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 10 (6%) were positive for BCL-3, including six of 23 (26%) diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one of 17 (6%) small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one of 26 (4%) follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two of 49 (4%) mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were negative, including marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=24, 11 extranodal, nine nodal, four splenic), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=10), lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=10), lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=8), and <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> (n=5) </plain></SENT>
<SENT sid="5" pm="."><plain>Of 111 T/NK-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 25 (23%) were positive for BCL-3, including 13 of 40 (32%) anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, three of 10 (30%) angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, two of eight (25%) extranodal NK/T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of nasal type, three of 12 (25%) <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e>, one of five (20%) <z:hpo ids='HP_0002242'>enteropathy</z:hpo>-type T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two of 21 (10%) peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> unspecified </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other T-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were negative, including lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=6), prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=6), and subcutaneous <z:mp ids='MP_0011164'>panniculitis</z:mp>-like T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=3) </plain></SENT>
<SENT sid="7" pm="."><plain>Of 70 Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, of <z:hpo ids='HP_0000001'>all</z:hpo> types, 29 (41%) were positive for BCL-3 </plain></SENT>
<SENT sid="8" pm="."><plain>The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types raises the possibility that BCL-3 is involved in the pathogenesis of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and may be a target of new therapies </plain></SENT>
</text></document>